In melanoma, the most common driver mutation occurring in over 50% of patients affects the serine/threonine protein kinase BRAF (BRAFV600E), a downstream effector of growth factor receptor signaling, that can be therapeutically targeted by specific BRAFV600mut inhibitors (BRAFi) [10]. Here, BRAF is linked to melanoma.